[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-vascular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-vascular":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,68,103,134,172,197,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100538341","home-tele-rehabilitation-therapy-for-vascular-dementia-100538341",false,"NCT06289569","Home Tele Rehabilitation Therapy for Vascular Dementia","Inclusion Criteria:\n\n* Symptomatic ischemic or hemorrhagic stroke verified by computerized axial tomography or magnetic resonance imaging\n* at least 6 months post stroke\n* At least some active movement in the affected upper extremity (MRS 1 or more in shoulder elbow or wrist)\n* Ability to provide informed consent, or LAR able to provide consent\n* Expressed willingness to comply with all study procedures and attend all study-related visits for both the patient and at least one caregiver.\n* Age ≥ 18.\n* Ability to follow one-step commands.\n* Community-dwelling with transportation to evaluation sessions.\n* Ability to operate the therapy system with minimal assistance, including sufficient corrected vision to perceive objects from a distance of 5 feet.\n* Modified Ashworth Scale Score 3 or less in the involved upper extremity\n* Passive range of motion within functional ranges at the shoulder, elbow, wrist and hand\n\nExclusion Criteria:\n\n* Patients with history of severe alcohol or drug abuse, psychiatric illnesses like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as unable to follow study instructions even with help from caregiver).\n* Patients with bilateral paresis, or weakness or sensory damage due to peripheral causes (e.g. peripheral nerve injury, muscle or orthopedic injury etc.)\n* Patients with severe uncontrolled medical problems that would render intensive rehabilitation unfeasible or unsafe (e.g. cardiovascular disease, unstable cardiac arrhythmia, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age, epilepsy or others).\n* Concurrent participation in other experimental upper extremity rehabilitation trials that would interfere with results.\n* Non-English-speaking individuals will only be eligible if they can provide the appropriate translator for all the sessions of the study as no funding is available to pay for such services. However, we plan to include them once funding has been secured in the subsequent larger trial.\n* Pregnancy\n* Prisoners","ALL","18 Years","110 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","To determine whether the home telerehabilitation therapy is feasible and lessens caregiver burden in chronic stroke patients with and without vascular dementia (VaD)",[26,27],"Dementia, Vascular","Stroke Sequelae","RECRUITING","2026-02-27",{"date":31,"type":32},"2026-03-02","ACTUAL",{"date":34,"type":32},"2024-12-14",{"date":36,"type":20},"2028-04-01",{"name":38,"class":39},"The Methodist Hospital Research Institute","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100432830","determinants-of-incident-stroke-cognitive-outcomes-and-vascular-effects-on-recovery-100432830","NCT04916210","Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY","DISCOVERY","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Admitted to the enrolling clinical performance site (CPS) hospital with a diagnosis of acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), or aneurysmal subarachnoid hemorrhage (aSAH)\n3. Radiographic confirmatory evidence of: (1) AIS (based on a focal area of restricted diffusion on MRI), (2) non-traumatic primary ICH (based on evidence of acute parenchymal hemorrhage on CT or brain MRI) or (3) non-traumatic acute aSAH (based on evidence of subarachnoid hemorrhage on CT or MRI and evidence of aneurysm on CT angiography, MR angiography, or conventional catheter-based angiography)\n4. Able to complete baseline visit in person or by phone within 6 weeks of stroke onset\n5. Able to provide informed consent by self or proxy\n6. Fluent in English or Spanish prior to stroke onset\n\nExclusion Criteria:\n\n1. Documented history of pre-stroke dementia or fails dementia pre-screen\n2. Concurrently enrolled into a study that is not approved under the DISCOVERY Co-Enrollment Policy\n3. Unable to complete study protocol (advanced directives such as comfort measures only, or inability to complete the study due to severe medical\u002Fbehavioral co-morbidities), as determined by physician investigator during screening process\n\n   Additional exclusion criteria for Tier 2 participants:\n4. Contraindication to MRI: presence of electrically, magnetically, or mechanically activated implants (such as cardiac pacemakers, cochlear implants, implanted pumps); or metallic clips in the brain\n\n   Additional exclusion criteria for Tier 3 participants:\n5. Age \\\u003C50 years\n6. Biologically female individuals who are pregnant or seeking to become pregnant\n7. Known to have one of the following genetic conditions which can increase the risk of developing cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, Down's syndrome.",{"count":49,"type":20},8000,"OBSERVATIONAL","The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a \"stroke\" is defined as either (1) an acute ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding around the brain caused by an abnormal bulge in a blood vessel that bursts).\n\nThe investigators hypothesize that:\n\n1. The size, type and location of the stroke play an important role in recovery of thinking and memory abilities after stroke, and pre-existing indicators of brain health further determine the extent of this recovery.\n2. Specific stroke events occurring in individuals with underlying genetic or biological risk factors can cause further declines in brain heath, leading to changes in thinking and memory abilities after stroke.\n3. Studying thinking and memory alongside brain imaging and blood samples in patients who have had a stroke allows for earlier identification of declining brain health and development of individualized treatment plans to improve patient outcomes in the future.",[53,54,55,26,56,57],"Ischemic Stroke","Intracerebral Hemorrhage","Subarachnoid Hemorrhage","Mild Cognitive Impairment","Vascular Cognitive Impairment","2025-10-31",{"date":60,"type":32},"2025-11-03",{"date":62,"type":32},"2021-03-05",{"date":64,"type":20},"2026-08-31",{"name":66,"class":39},"Massachusetts General Hospital",31,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":50,"phases":4,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":40},"100592421","home-based-brain-monitoring-with-a-garment-eeg-to-study-cognitive-decline-in-the-aging-population-100592421","NCT06993207","HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population","Validation of a Home-use Instrument for the Quantification of Cognitive Function in a Population at Risk of Dementia","Hogar","General Inclusion Criteria:\n\n* Native Spanish speaker.\n* Agree to the examination procedures and tests.\n* Ability to involve a close family member or friend for functional evaluation.\n* Normal or corrected-to-normal color vision.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion.\n* No severe psychiatric (according to DSM-V) or neurological diseases (epilepsy with frequent seizures (\\>1\u002Fmonth) in the last year, multiple sclerosis, etc.).\n* No diseases that may interfere with cognitive functions (renal insufficiency on hemodialysis, liver cirrhosis, chronic pulmonary disease with oxygen therapy, solid organ transplant, fibromyalgia, active cancer under treatment).\n* No severe hearing and\u002For visual impairments, neurodevelopmental, or psychomotor disorders.\n* No brain injuries that may interfere with cognitive functions (history of traumatic brain injury with parenchymal injury or macroscopic ischemic stroke of large extra-axial vessels or hemorrhagic stroke, brain surgery, brain tumors, or other causes that could result in acquired brain damage such as brain chemotherapy or radiotherapy).\n* No treatment with antipsychotic agents in the 6 months prior to the initial assessment.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion. No psychiatric or neurological medication.\n* No alcohol or drug abuse.\n* No serious health problems in the last 12 months (especially neurological or cardiac disorders).\n\nInclusion Criteria 'Mild Dementia' group:\n\n* Diagnosis of Alzheimer's type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Diagnosis of vascular or mixed type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Lack of autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment.\n\nInclusion Criteria 'Mild Cognitive Impairment' group:\n\n* Diagnosis of mild cognitive impairment, based on a clinical and cognitive assessment conducted by a physician.\n* Preserved autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment\n\nInclusion Criteria 'Subjective Cognitive Decline' group:\n\n* Adherence to SCD-I criteria.\n* Attendance at primary care consultation with memory complaints lasting more than 6 months.\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Onset of subjective cognitive decline in the last 5 years.\n* Concerns related to subjective cognitive decline (not associated with an acute event) expressed by the participant and\u002For an informant.\n* Cognitive performance within the normal range on cognitive tests (MMSE (Mini Mental State Exam) \\\u003C 26 \u002F MIS (Memory Impairment Screen) \\\u003C 6).\n* No severe depressive symptoms, indicated by scores \\> 17\\* on the 30-item Geriatric Depression Scale.\n\nInclusion criteria No impairment group:\n\n* Cognitive performance within the normal range on cognitive tests (MMSE \\\u003C 26 \u002F MIS \\\u003C 6).\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Not meeting the criteria for SCD-I \\[21\\].\n* Independent person living in their own home.\n* No subjective memory complaints.",true,"60 Years",{"count":79,"type":20},500,"3 Years","This study will investigate the validity of the HOGAR EEG\u002FPSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive decline. The kit consists of two EEG headbands and a mobile computing device that allows measurements of sleep patterns (PSG) and brain activity (EEG) in a home environment.",[83,56,84,85,86,26],"Dementia","Dementia Alzheimers","Dementia, Mixed","Subjective Cognitive Decline",[83,88,89,90,91,92],"MCI","Memory","cognitive decline","EEG","Sleep EEG","2025-05-19",{"date":95,"type":32},"2025-05-28",{"date":97,"type":32},"2024-01-15",{"date":99,"type":20},"2028-12-31",{"name":101,"class":102},"Bitbrain","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":40},"100516897","white-matter-hyperintensity-shape-and-glymphatics-100516897","NCT06010511","WHIte MAtter Hyperintensity Shape and Glymphatics","White Matter Hyperintensity Shape and Glymphatics","WHIMAS","Inclusion Criteria:\n\n* Admitted to the memory or the geriatric clinic of the LUMC, the Alrijne Hospital Leiden or the Haga Hospital the Hague\n* From 65 years of age\n* Eligible for MRI\n* Native-level Dutch speaker\n\nExclusion Criteria:\n\n* Claustrophobia\n* Contraindications for MRI such as metal implants and pacemaker\n* Use of benzodiazepines\n* Initiated treatment with antidepressants less than 6 weeks prior to inclusion\n* Not being able to provide written informed consent (assessed by the treating physician)\n* Individuals that have been declared mentally incapacitated\n* Other severe neurological disease besides dementia related\n* Cognitive impairment due to known other neurological disease\n* Previous brain surgery","65 Years",{"count":113,"type":20},50,"In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases. Impaired brain clearance is suggested to be closely related to dementia development, as waste products (e.g. amyloid beta) accumulate in the brain, leading to neurodegeneration. Cerebral small vessel disease (SVD) is the most common neurovascular disease that even contributes to about 45% of dementia pathophysiology in patients with a diagnosis of Alzheimer's dementia. White matter hyperintensities of presumed vascular origin (WMH) are the key brain MRI manifestation of cerebral SVD. There is evidence that the currently known and MRI-visible WMH are landmarks of an already progressed stage of the underlying pathology. The pathophysiology of WMH has been attributed to multiple underlying mechanisms, such as hypoperfusion, defective cerebrovascular reactivity and blood-brain barrier dysfunction. Furthermore, different anatomical locations and different types of WMH are related to different underlying pathological changes. Using ultra-high field 7T MR imaging techniques WMH lesions can be detected with a higher sensitivity and resolution than on 3T MRI. The hypothesis is that different pathological mechanisms of cerebral SVD lead to variations in WMH shape. Moreover, the brain clearance ('glymphatic') system of the brain appears to be tightly connected to dementia pathology. Thus, novel markers of glymphatic activity could aid to describe and understand the pathology.",[116,85,26,56,117,118],"Cerebral Small Vessel Diseases","Cognitive Impairment","Cognitive Decline",[120,121,122,123,90,124],"dementia","cerebral small vessel disease","White matter hyperintensities","cognitive impairment","Glymphatics","2025-04-10",{"date":127,"type":32},"2025-04-13",{"date":129,"type":32},"2023-01-18",{"date":131,"type":20},"2027-08-31",{"name":133,"class":39},"Leiden University Medical Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":76,"sex":15,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":153,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":40},"100572472","association-of-transcranial-alternating-current-stimulation-with-digital-cognitive-training-for-cognitive-remediation-in-older-adults-100572472","NCT06733714","Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults","Inclusion Criteria:\n\n* Healthy subjects over 50 years old, with cognitive complaints\n\nExclusion Criteria:\n\n* Estimated Intelligence Quotient \\\u003C80\n* Dependence on psychoactive substances (DSM-V)\n* Severe psychiatric or neurological disorders\n* Uncorrected visual\u002Fhearing problems\n* History of syncope for an unexplained reason or seizure less than a year ago\n* Previous stroke\n* Use of anticoagulants\n* Intracranial metallic prosthesis or cardiac pacemaker\n* Any contraindication to performing tACS","50 Years",{"count":142,"type":20},40,[23],"BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.\n\nDigital Cognitive Training (DCT) and Transcranial Alternating Current Stimulation (tACS) are two promising tools for cognitive remediation in this population. In this exploratory study, we investigate feasibility, tolerability and preliminary effects of the association of both interventions in older adults with cognitive complaints.\n\nMETHODS Older adults with cognitive complaints are being enrolled for this study, which comprises 5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving theta tACS (6Hz, 1.6mA) targeting the Left Dorsolateral Prefrontal Cortex.",[146,147,56,118,148,83,26,149,150,151,152],"Cognitive Dysfunction","Alzheimer Disease","Frontotemporal Degeneration","Lewy Body Disease","Beta-Amyloid","GFAP","Tau Protein",[154,155,156,157,88,158,159,160,161,162],"tacs","nibs","transcranial alternate current stimulation","mild cognitive impairment","ALzheimer","Cognition","Elderly","Older Adults","Cognitive enhancement","2024-12-09",{"date":165,"type":32},"2024-12-13",{"date":167,"type":32},"2024-12-02",{"date":169,"type":20},"2027-03-01",{"name":171,"class":39},"Universidade Federal do Rio de Janeiro",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":15,"minAge":140,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":40},"100555590","phase-2-cannabidiols-role-in-dementia-management-100555590","NCT06514066","Cannabidiol's Role in Dementia Management","Cannabidiol's Role in Dementia Management: Evaluating Cognitive, Quality of Life, and Well-being Outcomes in Malaysia","MyC4D","Inclusion Criteria:\n\n1. Age: Participants (male and female) must be 50 years of age or older at the time of enrollment. This criterion is necessary to ensure that participants can legally provide informed consent for their participation.\n2. Diagnosis: Participants must have a confirmed diagnosis of mild to severe dementia based on DSM-5 and Clinical Dementia Rating (CDR). Diagnosis should be confirmed by either neurologist, psychiatrist or geriatrician that attend the pattients.\n3. Stability of Condition: Participants' disease status must be stable at the time of enrollment, as determined by the investigator. For example, seizure frequency for those with epilepsy should be consistent for a specified period (e.g., the past three months) before study entry.\n4. Consent: The caregivers of the participants must provide written informed consent to participate in the study. The consent form must be read, understood, and signed by the caregivers before any study-specific procedures are performed.\n5. Ability to Comply: Participants' caregivers must be willing and able to comply with all study procedures and requirements needed by the study. The caregivers must ensure that the participants has the ability to ingest oral medication, and they need to complete surveys on behalf of the participants on their phone, record log seizures (if applicable), and bring the patients to attend all necessary study visits.\n6. Health Status: Participants must be in a health state, as determined by the investigator that will not put them at undue risk of harm from participating in the study or interfere with the study's ability to achieve its objectives.\n7. Additional Criteria for Cancer Patients: Cancer patients must not be on any active chemotherapy and radiation treatment, as determined by the investigator.\n\nThe exact specifications of these criteria will be determined in consultation with Malaysian clinical experts and will be clearly defined in the study's protocol. These criteria are intended to ensure the study's results are valid, reliable, and applicable to the target population.\n\nExclusion Criteria:\n\n1. Cannot fulfil all the requirement as above.\n2. Substance Use: Active usage of substances\u002Fmedications such as cocaine, opiates, benzodiazepines, barbiturates, amphetamines, morphine, methadone, methamphetamines, oxycodone, phencyclidine, tricyclic antidepressants, tetrahydrocannabinol, buprenorphine, methylenedioxymethamphetamine, propoxyphene.\n3. Concurrent Treatments: Participants currently participating in another clinical trial or using other experimental treatments for their condition. Participants who have used any medication, dietary supplements (and\u002For grapefruit juice), or combination of medications and supplements known to alter the metabolism of, or interact with CBD (bupropion, rifampin, barbiturates, phenothiazines, cimetidine, etc.) 14 days prior to and during the duration of the study.\n4. Significant Health Risks: Participants with significant cardiovascular, hepatic, renal, respiratory, or psychiatric disease, which, in the investigator's opinion, would place the participant at undue risk or interfere with the results of the study. History of impaired renal function or elevated liver enzymes at prescreening. The exclusionary lab values are: 3x nl AST\u002FALT, 1.5x bilirubin or eGFR less than 30 ml\u002Fmin. Having present or past medical conditions, including a DSM-5 Axis I psychiatric disorder, history of cardiac disease, arrhythmias, neurological disease of central origin, head trauma, and seizures.\n5. Hypersensitivity: Individuals with known hypersensitivity to CBD or any component of the study formulation.",{"count":181,"type":20},486,[183,184],"PHASE2","PHASE3","This trial investigates the therapeutic benefits of cannabidiol (CBD) for Dementia patients in Malaysia. As dementia becomes increasingly prevalent worldwide, there's a pressing demand for impactful remedies. This research will delve into CBD's influence on cognitive functions, daily activities, mental health, and overall life quality of dementia sufferers. Utilizing a range of established assessment instruments, including the ADAS-COG subscale for cognitive effects, the NPI score for psychological well-being, and the QOLAD questionnaire for life quality, we aim to discern CBD's potential in ameliorating the conditions of those with dementia. This study's results could shape novel treatment methods and improved care for dementia patients, benefiting not just Malaysia but the world at large.",[26,85],"NOT_YET_RECRUITING","2024-07-17",{"date":190,"type":32},"2024-07-23",{"date":192,"type":20},"2024-09-01",{"date":194,"type":20},"2025-10-01",{"name":196,"class":39},"Hospital Pengajar Universiti Putra Malaysia",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":76,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":207,"conditions":208,"keywords":213,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":40},"100507277","the-imperial-comprehensive-cognitive-assessment-in-cerebrovascular-disease-ic3-100507277","NCT05885295","The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)","Understanding Factors Affecting Cognitive Function in Cerebrovascular Disease","IC3","Inclusion Criteria:\n\n* Aged \\> 18\n* Evidence of confirmed stroke (for patients)\n* Ability to concentrate for 15 minutes at a time to engage with cognitive testing\n\nExclusion Criteria for the main study:\n\n* Pre-stroke diagnosis of dementia\n* Severe visuo-spatial problems, fatigue, or mental health problems\n* Severe hearing impairment in the presence of reading comprehension impairment\n\nExclusion Criteria for the MRI imaging sub-study:\n\n* Pregnancy\n* Presence of metal implants\n* Claustrophobia",{"count":206,"type":20},700,"Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors. These deficits negatively impact recovery and therapy engagement, and their treatment is consistently rated as high priority by stakeholders and clinicians. Although clinical guidelines endorse cognitive screening for post-stroke management, there is currently no gold standard approach for identifying cognitive deficits after stroke, and clinical stroke services lack the capacity for long-term cognitive monitoring and care. Currently available assessment tools are either not stroke-specific, not in-depth or lack scalability, leading to heterogeneity in patient assessments. To address these challenges, a cost-effective, scalable, and comprehensive screening tool is needed to provide a stroke-specific assessment of cognition. The current study presents such a novel digital tool, the Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3), designed to detect both domain-general and domain-specific cognitive deficits in patients after stroke with minimal input from a health professional. To ensure its reliability, we will utilise multiple validation approaches, and aim to recruit a large normative sample of age-, gender-, and education-matched UK-based controls. Moreover, the IC3 assessment will be integrated within a larger prospective observational longitudinal clinical trial, where post-stroke cognition will be examined in tandem with brain imaging and blood biomarkers to identify novel multimodal biomarkers of recovery after stroke. By leveraging this rich dataset, our study will allow more precise targeting of cognitive rehabilitation to stroke survivors that are most at risk of progressive cognitive decline and have the greatest potential for recovery.",[209,210,26,211,212,117],"Stroke","Stroke (CVA) or TIA","Cerebrovascular Disorders","Small Vessel Cerebrovascular Disease",[120,214,215,216,217,218,151,219,220,221,123,222,223,224,225],"MRI","blood biomarkers","neurofilament light","amyloid","tau","white matter hyper intensity","micro bleed","small vessel disease","vascular dementia","stroke","aphasia","neglect","2023-05-30",{"date":228,"type":32},"2023-06-01",{"date":230,"type":32},"2021-12-01",{"date":232,"type":20},"2028-05-15",{"name":234,"class":39},"Imperial College London",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":76,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":40},"100441071","pumch-dementia-longitudinal-cohort-study-100441071","NCT05023564","PUMCH Dementia Longitudinal Cohort Study","Peking Union Medical College Hospital (PUMCH) Dementia Longitudinal Cohort Study","Inclusion Criteria:\n\n* Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia\n* Fixed care giver and can follow up regularly\n\nExclusion Criteria:\n\n* Not demented, including MCI\n* Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation\n* Without fixed care giver\n* Reject informed consent\n* Expected life shorter than 2 years",{"count":243,"type":20},20000,"The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.",[83,26,246,85,84,247,248],"Dementia With Lewy Bodies","Dementia Frontal","Dementia, Mild","2022-09-10",{"date":251,"type":32},"2022-09-13",{"date":253,"type":32},"2020-12-01",{"date":255,"type":20},"2040-12-31",{"name":257,"class":39},"Peking Union Medical College Hospital"]